# Cancer Treatment and Pharmacology

**Type:** Topics  
**Canonical URL:** https://scholariq.org/topics/cancer-treatment-and-pharmacology/

## Facts

| Field | Value |
| --- | --- |
| Description | This cluster of papers focuses on the chemotherapy-induced peripheral neuropathy (CIPN) experienced by cancer patients, particularly in the context of breast cancer treatment. It covers various aspects such as the neurotoxic effects of taxanes and oxaliplatin, neuroprotective strategies, and the impact of CIPN on the quality of life of patients. Additionally, it discusses the use of microtubule-targeting agents like Eribulin Mesylate in cancer treatment. |
| Domain | Health Sciences |
| Field | Medicine |
| OpenAlex ID | t11752 |
| Works | 302 |

## Topic papers all

Showing 15 of 302.

- [Use of Chemotherapy plus a Monoclonal Antibody against HER2 for Metastatic Breast Cancer That Overexpresses HER2](https://scholariq.org/papers/use-of-chemotherapy-plus-a-monoclonal-antibody-against-her2-for-metastatic/)
- [A simple method for clinical assay of superoxide dismutase.](https://scholariq.org/papers/a-simple-method-for-clinical-assay-of-superoxide-dismutase/)
- [Paclitaxel plus Bevacizumab versus Paclitaxel Alone for Metastatic Breast Cancer](https://scholariq.org/papers/paclitaxel-plus-bevacizumab-versus-paclitaxel-alone-for-metastatic-breast-cancer/)
- [Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer](https://scholariq.org/papers/chemohormonal-therapy-in-metastatic-hormone-sensitive-prostate-cancer/)
- [Trastuzumab Emtansine for Residual Invasive HER2-Positive Breast Cancer](https://scholariq.org/papers/trastuzumab-emtansine-for-residual-invasive-her2-positive-breast-cancer/)
- [Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer](https://scholariq.org/papers/trastuzumab-deruxtecan-in-previously-treated-her2-low-advanced-breast-cancer/)
- [Antitumor Activity of Thalidomide in Refractory Multiple Myeloma](https://scholariq.org/papers/antitumor-activity-of-thalidomide-in-refractory-multiple-myeloma/)
- [Overall Survival Results of a Trial Assessing Patient-Reported Outcomes for Symptom Monitoring During Routine Cancer Treatment](https://scholariq.org/papers/overall-survival-results-of-a-trial-assessing-patient-reported-outcomes-for/)
- [Polychemotherapy for early breast cancer: an overview of the randomised trials. Early Breast Cancer Trialists' Collaborative Group.](https://scholariq.org/papers/polychemotherapy-for-early-breast-cancer-an-overview-of-the-randomised-trials/)
- [Phase III Trial of Nanoparticle Albumin-Bound Paclitaxel Compared With Polyethylated Castor Oil–Based Paclitaxel in Women With Breast Cancer](https://scholariq.org/papers/phase-iii-trial-of-nanoparticle-albumin-bound-paclitaxel-compared-with/)
- [3rd ESO–ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 3)](https://scholariq.org/papers/3rd-eso-esmo-international-consensus-guidelines-for-advanced-breast-cancer-abc-3/)
- [A History of Cancer Chemotherapy](https://scholariq.org/papers/a-history-of-cancer-chemotherapy/)
- [Adjuvant Capecitabine for Breast Cancer after Preoperative Chemotherapy](https://scholariq.org/papers/adjuvant-capecitabine-for-breast-cancer-after-preoperative-chemotherapy/)
- [Vinorelbine plus Cisplatin vs. Observation in Resected Non–Small-Cell Lung Cancer](https://scholariq.org/papers/vinorelbine-plus-cisplatin-vs-observation-in-resected-non-small-cell-lung-cancer/)
- [Doxorubicin pathways](https://scholariq.org/papers/doxorubicin-pathways/)

## Topic primary papers

Showing 15 of 78.

- [A simple method for clinical assay of superoxide dismutase.](https://scholariq.org/papers/a-simple-method-for-clinical-assay-of-superoxide-dismutase/)
- [Paclitaxel plus Bevacizumab versus Paclitaxel Alone for Metastatic Breast Cancer](https://scholariq.org/papers/paclitaxel-plus-bevacizumab-versus-paclitaxel-alone-for-metastatic-breast-cancer/)
- [Phase III Trial of Nanoparticle Albumin-Bound Paclitaxel Compared With Polyethylated Castor Oil–Based Paclitaxel in Women With Breast Cancer](https://scholariq.org/papers/phase-iii-trial-of-nanoparticle-albumin-bound-paclitaxel-compared-with/)
- [A History of Cancer Chemotherapy](https://scholariq.org/papers/a-history-of-cancer-chemotherapy/)
- [Breast Cancer, Version 3.2020, NCCN Clinical Practice Guidelines in Oncology](https://scholariq.org/papers/breast-cancer-version-3-2020-nccn-clinical-practice-guidelines-in-oncology/)
- [Randomized Phase III Trial of Capecitabine Compared With Bevacizumab Plus Capecitabine in Patients With Previously Treated Metastatic Breast Cancer](https://scholariq.org/papers/randomized-phase-iii-trial-of-capecitabine-compared-with-bevacizumab-plus/)
- [Bevacizumab (Avastin®) in cancer treatment: A review of 15 years of clinical experience and future outlook](https://scholariq.org/papers/bevacizumab-avastin-in-cancer-treatment-a-review-of-15-years-of-clinical/)
- [Prevention and Management of Chemotherapy-Induced Peripheral Neuropathy in Survivors of Adult Cancers: ASCO Guideline Update](https://scholariq.org/papers/prevention-and-management-of-chemotherapy-induced-peripheral-neuropathy-in/)
- [RIBBON-1: Randomized, Double-Blind, Placebo-Controlled, Phase III Trial of Chemotherapy With or Without Bevacizumab for First-Line Treatment of Human Epidermal Growth Factor Receptor 2–Negative, Locally Recurrent or Metastatic Breast Cancer](https://scholariq.org/papers/ribbon-1-randomized-double-blind-placebo-controlled-phase-iii-trial-of/)
- [Neoadjuvant carboplatin in patients with triple-negative and HER2-positive early breast cancer (GeparSixto; GBG 66): a randomised phase 2 trial](https://scholariq.org/papers/neoadjuvant-carboplatin-in-patients-with-triple-negative-and-her2-positive-early/)
- [Phase I and Pharmacokinetic Study of Genexol-PM, a Cremophor-Free, Polymeric Micelle-Formulated Paclitaxel, in Patients with Advanced Malignancies](https://scholariq.org/papers/phase-i-and-pharmacokinetic-study-of-genexol-pm-a-cremophor-free-polymeric/)
- [Chemotherapy‐induced peripheral neurotoxicity: A critical analysis](https://scholariq.org/papers/chemotherapy-induced-peripheral-neurotoxicity-a-critical-analysis/)
- [Prospective Randomized Trial of Docetaxel Versus Doxorubicin in Patients With Metastatic Breast Cancer](https://scholariq.org/papers/prospective-randomized-trial-of-docetaxel-versus-doxorubicin-in-patients-with/)
- [Chemotherapy-induced peripheral neuropathy: Prevention and treatment strategies](https://scholariq.org/papers/chemotherapy-induced-peripheral-neuropathy-prevention-and-treatment-strategies/)
- [Paclitaxel by 3-hour infusion in combination with bolus doxorubicin in women with untreated metastatic breast cancer: high antitumor efficacy and cardiac effects in a dose-finding and sequence-finding study.](https://scholariq.org/papers/paclitaxel-by-3-hour-infusion-in-combination-with-bolus-doxorubicin-in-women/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.